Targa Therapies SA
Executive Summary
Targa Therapies marries gene therapy and monoclonal antibodies in its proprietary Antibody Delivery System, which it believes will help circumvent many of the flaws in current gene therapies.
You may also be interested in...
Protiva Biotherapeutics Inc.
Protiva Biotherapeutics is using liposomes to deliver plasmids, or pieces of DNA. The liposome cover does two things; it protects the plasmid from being quickly degraded in the circulation. And it improves targeting to tumors, since liposomes gather preferentially at sites of vascular leakage--generally the disorganized vasculatures of tumors.
Antiviral Sentiment
The alarm bell is ringing for companies developing adenoviral vectors for gene therapies, particularly those meant to treat liver disease. But every firm in the field is now on alert.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?